CABIO Biotech (Wuhan) Co., Ltd (Abbreviated as "CABIO") is a biotechnology company that provides high-quality nutrient products and innovative solutions to the customers in nutrition and health around the globe. CABIO utilizes biosynthetic technology as its core and conducts industrial production through sustainable production mode of microbial synthesis with the integrated technology of Directional industrial strains optimization, Fine control of fermentation and High efficiency separation and purification.
CABIO is mainly specialized in development, production and sales of food ingredients including Arachidonic acid (ARA), Docosahexaenoic acid (DHA), natural β-Carotene and Sialic acid (SA), and its products are widely used in Infant formula food, dietary supplements, health food and Formula food for special medical use and etc.
CABIO is a high-tech enterprise in China which is one of the earliest companies engaged in the production of high value nutrients by fermentation process such as polyunsaturated fatty acids, and it is one of the leading global suppliers of ARA products.
CABIO has established two major production sites which comply with the most advanced international standards and a complete international supply chain and service system. Sales of CABIO's products covers China, the United States, Europe, Australia, New Zealand, South Korea, Southeast Asia and more than 30 countries and regions.
CABIO has mastered the core technology of microbial fermentation, and has consistently taken technological innovation as the core driving force and established a mature system of technological innovation. It has undertaken the National High-Tech Research and Development Program of China (863 Program), and has led the drafting in the formulation of national food safety standards for ARA and DHA oils derived from Fermentation methods. Up to now, CABIO has applied for a total of 113 patents, of which 105 invention patents, PCT 10, and 35 patents have been granted. CABIO's technology and products have won the second-class National Science and Technology Progress Award, the first-class Chinese Agricultural Science and Technology Progress Award of the Ministry of Agriculture, the first-class Technological Progress Award of the China Dairy Association, and the first-class Scientific and technological progress award of Hubei Province.
| Full name | CABIO Biotech (Wuhan) Co., Ltd |
|---|---|
| Abbreviations | CABIO |
| Code | 688089 |
| Founded | September 22,2004 |
| Listing | December 19,2019 |
| Domicile | Wuhan, Hubei |
| Website | http://www.cabio.cn/ |
| zqb@cabio.cn | |
| STAR Theme | Biomedicine |
| CSRC Sector | Food Manufacturing |
| Has weighted voting rights structure? | No |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Earnings Per Share | 1.09 | 1.31 | 1.08 |
| R&D expenditure as a % of operating revenue | 6.30% | 6.01% | 5.72% |
| Operating Revenue | 323 | 312 | 286 |
| Net Income | 135 | 120 | 98 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Operating Revenue | 323 | 312 | 286 |
| Operating Costs | 145 | 147 | 146 |
| Operating Income | 124 | 99 | 81 |
| Pretax Income | 158 | 140 | 114 |
| Income Tax | 23 | 19 | 16 |
| Net Income | 135 | 120 | 98 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Assets | |||
| Current Assets-Total | 1123 | 1099 | 369 |
| Non-current Assets-Total | 260 | 199 | 212 |
| Total Assets | 1382 | 1297 | 581 |
| Liabilities | |||
| Current Liabilities-Total | 52 | 42 | 50 |
| Non-current Liabilities-Total | 7 | 6 | 5 |
| Total Liabilities | 59 | 48 | 55 |
| Stockholder's Equity | |||
| Share Capital | 120 | 120 | 90 |
| Retained Profits | 327 | 257 | 184 |
| Total Owners' Equity | 1323 | 1249 | 526 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Net Cash Flows-Operating | 146 | 132 | 106 |
| Net Cash Flows-Investing | -80 | -13 | -26 |
| Net Cash Flows-Financing | -64 | 603 | -36 |
| Name | No. of Shares Held (mn) | % of Shares Held |
|---|---|---|
| 武汉烯王生物工程有限公司 | 53.10 | 44.25% |
| 贝优有限公司 | 20.25 | 16.87% |
| 永新县嘉宜和管理咨询中心（有限合伙） | 5.99 | 4.99% |
| 杭州源驰投资合伙企业（有限合伙） | 3.88 | 3.23% |
| 湖北省轻工业品进出口股份有限公司 | 2.35 | 1.96% |
| 国泰君安证券资管－南京银行－国泰君安君享科创板嘉必优1号战略配售集合资产管理计划 | 1.13 | 0.94% |
| 招商银行股份有限公司－富国科创板两年定期开放混合型证券投资基金 | 0.96 | 0.80% |
| 周建国 | 0.80 | 0.67% |
| 刘国永 | 0.64 | 0.54% |
| 招商银行股份有限公司－富国天合稳健优选混合型证券投资基金 | 0.58 | 0.48% |
All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.
Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.
Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.